Genetic Screening Capabilities of PGT
Georgia's third-generation IVF technology (PGT, Preimplantation Genetic Testing) can screen for specific genetic diseases, but not all genetic conditions are covered. PGT is currently divided into three types: PGT-A (aneuploidy screening), PGT-M (monogenic disorder testing), and PGT-SR (chromosomal structural rearrangement testing). In licensed reproductive centers in Georgia, PGT-A is a basic screening item that can detect whether embryos have chromosomal aneuploidies (such as trisomy 21, trisomy 18, trisomy 13, and sex chromosome abnormalities). PGT-M requires clear information on the pathogenic gene locus and is suitable for couples known to carry specific pathogenic genes, such as cystic fibrosis, spinal muscular atrophy (SMA), thalassemia, hereditary deafness, and other monogenic disorders. PGT-SR targets carriers of structural abnormalities such as balanced chromosomal translocations and Robertsonian translocations. Therefore, answering whether "Georgia PGT can screen for genetic diseases" requires distinguishing between screening for chromosomal disorders and monogenic diseases. The former is routinely covered, while the latter depends on the genetic diagnosis data of the proband or both partners.
Which Genetic Diseases Can Be Screened by Georgia PGT
According to current reproductive medicine practice, the following types of genetic diseases can be screened via PGT in Georgia:
| Type of Genetic Disease | Screening Possible | Prerequisites Required |
|---|---|---|
| Chromosomal aneuploidies (Down syndrome, Edwards syndrome, etc.) | Yes (PGT-A) | No additional genetic information needed; direct testing after embryo biopsy |
| Chromosomal structural abnormalities (balanced translocations, inversions, etc.) | Yes (PGT-SR) | Requires karyotype analysis results of the couple |
| Autosomal recessive disorders (SMA, thalassemia, etc.) | Yes (PGT-M) | Requires clear identification of pathogenic gene and mutation site |
| Autosomal dominant disorders (Marfan syndrome, Huntington's disease, etc.) | Yes (PGT-M) | Requires patient genetic diagnosis confirming the pathogenic mutation |
| X-linked recessive disorders (hemophilia, Duchenne muscular dystrophy, etc.) | Yes (PGT-M or sex selection) | Requires determination of carrier status and gene locus |
| Mitochondrial genetic disorders | Partially screenable | Requires mitochondrial DNA mutation load analysis; technically complex |
| Polygenic disorders (diabetes, hypertension, etc.) | No | Current PGT technology cannot assess polygenic risk |
| De novo mutations and genetic diseases with unidentified pathogenic genes | No | Lack of detection targets |
It should be clarified that the implementation of PGT-M requires the couple to have identified the pathogenic gene through genetic counseling and genetic testing. If they only have a "high-risk family history" without genetic confirmation, reproductive centers in Georgia usually require completing genetic diagnosis first.
Easily Overlooked Details: The Screening Boundaries of PGT
From a clinical perspective, three points are most easily overlooked:
- PGT cannot screen for all genetic diseases. For example, de novo mutations, mosaic embryos, and rare diseases with currently unknown genetic loci cannot be covered by PGT.
- PGT-M requires establishing a testing protocol in advance. Usually, a blood sample from the proband or parents is needed to complete probe design before embryo testing, a process that takes 4-8 weeks.
- PGT cannot replace prenatal diagnosis. Even after transferring PGT-screened embryos, amniocentesis or chorionic villus sampling is still recommended during pregnancy for confirmation, as embryo biopsy has limitations and cannot 100% rule out all genetic abnormalities.
Differences Between Georgia and Other Countries
Compared to some countries, Georgia's regulation of PGT technology is relatively clear, allowing sex chromosome screening and non-medical sex selection (prohibited in some countries). However, the scope of PGT-M testing in Georgia is limited by the laboratory's gene database and probe resources. For rare mutations, samples may need to be sent to partner laboratories in Europe (e.g., Germany or the Czech Republic) for testing, which increases time and transportation costs. Additionally, some reproductive centers in Georgia perform embryo biopsy for PGT at the blastocyst stage on days 5-6, consistent with mainstream international standards, but a few centers may use cleavage-stage biopsy on day 3, which carries a slightly higher risk of mosaicism. It is recommended to confirm before starting whether the laboratory has full-process capability for PGT-M, not just PGT-A.
Actual Process: From Genetic Counseling to Embryo Screening
The standard pathway for completing PGT genetic disease screening in Georgia is as follows:
- Genetic Counseling and Genetic Testing: Both partners must provide a complete family history and complete targeted gene sequencing or karyotype analysis. For known pathogenic genes, the genetic report of the proband (affected family member) must be provided.
- Probe Design and Validation: The embryology laboratory designs monogenic disease detection probes or SNP linkage analysis protocols based on genetic information. This step takes 4-6 weeks.
- Ovarian Stimulation and In Vitro Fertilization: Standard ovarian stimulation protocol, followed by ICSI insemination after egg retrieval to avoid paternal contamination.
- Blastocyst Culture and Biopsy: Biopsy at the blastocyst stage on days 5-6, taking 3-5 trophectoderm cells for testing.
- Genetic Testing: PGT-A uses NGS (next-generation sequencing) or aCGH (array comparative genomic hybridization); PGT-M uses PCR combined with linkage analysis or whole genome amplification followed by sequencing.
- Result Interpretation and Transfer: Test reports typically take 7-14 working days. Embryos that are chromosomally normal and do not carry the pathogenic gene are selected for frozen transfer.
- Post-Transfer Confirmation: Prenatal genetic diagnosis (amniocentesis) is recommended after pregnancy for verification.
Risks and Precautions
PGT itself carries certain technical risks and limitations:
- Risk of misdiagnosis due to embryo mosaicism: Blastocysts may contain a mix of normal and abnormal cells. The biopsied cells may not be representative, leading to false negatives or false positives.
- Risk of no transferable embryos: For carriers of chromosomal translocations or older women, all embryos may be abnormal, resulting in no embryos available for transfer.
- Risk of test failure: DNA amplification failure or low probe binding efficiency may result in no result for approximately 1-3% of embryos.
- Cost factors: The custom probe cost for PGT-M is typically €2,000-€5,000. Combined with the base cost of PGT-A and embryo biopsy, the total additional expense may increase by €3,000-€8,000.
Frequently Asked Questions
Q: What materials are needed for PGT-M in Georgia?
A: Genetic test reports for both partners (clearly identifying the pathogenic gene and locus), the proband's genetic report (if available), and genetic counseling records. Some centers may require a semen analysis and female ovarian function assessment report from the last 3 months.
Q: If there is no clear family history of genetic disease, is PGT still necessary?
A: For advanced maternal age (≥38 years) or recurrent implantation failure, only PGT-A for chromosomal aneuploidy screening is usually recommended; PGT-M is not needed. PGT-M is only for known carriers of pathogenic genes.
Q: Are PGT results from Georgia recognized by other countries?
A: The test report itself has reference value, but different countries have different regulatory standards for PGT. It is advisable to consult with the reproductive center in the destination country before transfer regarding acceptance of PGT reports from abroad.
Practitioner Observations
In practice, some patients have overly high expectations of PGT, believing that third-generation IVF can "eliminate all genetic diseases." In reality, PGT is a high-risk screening tool whose core value lies in reducing the transmission risk of known genetic disorders, not a guarantee of a "perfect baby." For de novo mutations, polygenic diseases, and epigenetic abnormalities, PGT is currently powerless. Additionally, reproductive centers in Georgia rely heavily on foreign genetic testing companies for PGT-M. It is recommended to confirm whether full local testing capabilities exist before starting, to avoid cycle cancellations due to sample shipping delays.
Risk Reminder: PGT technology itself does not increase the live birth rate. For couples who are not of advanced age and have no genetic disease risk, routine PGT is not recommended. All embryo testing carries a risk of misdiagnosis, and the final genetic outcome should be confirmed with prenatal diagnosis. Do not view PGT as a means to "guarantee a healthy child," but rather as a scientific tool to reduce the risk of specific genetic diseases.
Comments (0)